{"schema_version":"1","generated_at":"2026-11-20T14:35:54.322Z","data_as_of":null,"url":"https://www.findmykol.com/kol/shailendra-lakhanpal","json_url":"https://www.findmykol.com/kol/shailendra-lakhanpal/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"shailendra-lakhanpal","name":"Shailendra Lakhanpal","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"St. Vincent's Birmingham","institution_url":"https://www.findmykol.com/institution/st-vincent-s-birmingham","city":"Birmingham","state":"AL","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Shailendra Lakhanpal is an Oncology physician affiliated with St. Vincent's Birmingham. OpenAlex indexes 25 publications with 792 citations (h-index 5).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":25,"cited_by_count":792,"h_index":5,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":67,"program_years":{"first":2021,"last":null},"rows_total":191,"shown":3,"withheld":188,"rows":[{"payer":"Puma Biotechnology","program_year":2025,"amount_usd":18700,"payment_count":1},{"payer":"Genentech","program_year":2025,"amount_usd":6011,"payment_count":3},{"payer":"AVYXA PHARMA, LLC","program_year":2025,"amount_usd":3150.8,"payment_count":6}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":12,"areas_shown":3,"areas":[{"area":"Blood & clotting","share_pct":83.3,"classes_total":5,"classes":[{"class":"Iron, parenteral preparations","setting":"administered","share_pct":60.8,"drugs":[{"name":"Ferric carboxymaltose","share_pct":100}],"max_beneficiaries":32},{"class":"Erythropoiesis-stimulating Agent","setting":"administered","share_pct":22.2,"drugs":[{"name":"Darbepoetin alfa","share_pct":100}],"max_beneficiaries":13}]},{"area":"Metabolism & gastrointestinal","share_pct":8.6,"classes_total":9,"classes":[{"class":"Substance P/Neurokinin-1 Receptor Antagonist","setting":"administered","share_pct":6.1,"drugs":[{"name":"Aprepitant","share_pct":100}],"max_beneficiaries":13},{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":1.9,"drugs":[{"name":"Palonosetron hcl","share_pct":83.7},{"name":"Ondansetron Hcl","share_pct":13.9},{"name":"Ondansetron Odt","share_pct":2.4}],"max_beneficiaries":null}]},{"area":"Musculoskeletal","share_pct":3.5,"classes_total":2,"classes":[{"class":"RANK Ligand Inhibitor","setting":"administered","share_pct":3.4,"drugs":[{"name":"Denosumab","share_pct":100}],"max_beneficiaries":16},{"class":"gamma-Aminobutyric Acid-ergic Agonist","setting":"prescribed","share_pct":0,"drugs":[{"name":"Baclofen","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":99.6,"facility_pct":0.4},"source":"medicare"},"publications":{"total":25,"shown":5,"withheld":20,"matched_by":"OpenAlex author record","recent":[{"title":"Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative ( HR +/ HER2 −) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study","year":2026,"journal":"Cancer Medicine","source_url":"https://doi.org/10.1002/cam4.71788","status":"verified"},{"title":"Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents","year":2025,"journal":"JTO Clinical and Research Reports","source_url":"https://doi.org/10.1016/j.jtocrr.2025.100829","status":"verified"},{"title":"Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study","year":2025,"journal":"JCO Precision Oncology","source_url":"https://doi.org/10.1200/po-24-00810","status":"verified"},{"title":"Enhancing the interpretation of real-world quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer enrolled in the POLARIS study","year":2025,"journal":"The Oncologist","source_url":"https://doi.org/10.1093/oncolo/oyaf281","status":"verified"},{"title":"Relationship of Prior Anticancer Treatments with Palbociclib Clinical Outcomes in Patients with HR+/HER2− Advanced Breast Cancer in Real-World Settings","year":2025,"journal":"Targeted Oncology","source_url":"https://doi.org/10.1007/s11523-025-01158-0","status":"verified"}],"source":"works"},"similar":[{"name":"Ira Gore","slug":"ira-gore","institution":"St. Vincent's Birmingham","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/ira-gore","json_url":"https://www.findmykol.com/kol/ira-gore/profile.json"},{"name":"Parvez Sultan","slug":"parvez-sultan","institution":"St. Vincent's Birmingham","specialty":"Thoracic Surgery (Cardiothoracic Vascular Surgery)","url":"https://www.findmykol.com/kol/parvez-sultan","json_url":"https://www.findmykol.com/kol/parvez-sultan/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":188,"publications":20}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}